View Published SNOMED CT Subset Metadata

Enhanced Services Immunosuppressant drugs


Subset Name :   
Enhanced Services Immunosuppressant drugs
Subset Original Id :   
990201000001137
Subset Type :   
Realm Concept

Refset FSN :   
Enhanced services general practice extraction - Immunosuppressant drugs simple reference set (foundation metadata concept)
Refset Id :   
999000861000001107
Refset Type :   
Simple

Subset Description :
This subset identifies the VMPs and AMPs in dm+d that are identified as being immunosuppressive drugs within scope of the Enhanced Services Pneumococcal vaccination and immunisation and the Seasonal Flu vaccination and immunisation business rules. All VMPs and AMPs associated with the following VTMs: Adalimumab Alemtuzumab Crisantaspase Vindesine Vincristine Vinblastine Vinorelbine Amsacrine Azathioprine Anakinra Basiliximab Leflunomide Lomustine Bexarotene Bleomycin Busulfan Capecitabine Carboplatin Chlorambucil Cisplatin Cladribine Pentostatin Melphalan Cyclophosphamide Mercaptopurine Cytarabine Dacarbazine Daclizumab Dactinomycin Daunorubicin Tioguanine Thiotepa Topotecan Trastuzumab Treosulfan Sirolimus Tacrolimus Tegafur + Uracil Rituximab Temoporfin Temozolomide Epirubicin Estramustine Etanercept Etoposide Fluorouracil Docetaxel Doxorubicin Gemcitabine Idarubicin Ifosfamide Infliximab Irinotecan Methotrexate Mitomycin Mitoxantrone Procarbazine Raltitrexed Razoxane Bortezomib Oxaliplatin Paclitaxel Penicillamine Cetuximab Efalizumab Imatinib Carmustine Pemetrexed Verteporfin Anagrelide Bevacizumab Mycophenolate mofetil Mycophenolic acid Doxorubicin (liposomal) Arsenic Ciclosporin Erlotinib Fludarabine Sodium aurothiomalate Hydroxycarbamide Mitotane Antithymocyte immunoglobulin (rabbit) Daunorubicin (liposomal) Natalizumab Sorafenib Clofarabine Muromonab-CD3 Sunitinib Antithymocyte immunoglobulin (equine) Dasatinib Cytarabine (liposomal) Abatacept Lenalidomide Eculizumab Nelarabine Panitumumab Nilotinib Lapatinib Temsirolimus Ustekinumab Azacitidine Gefitinib Everolimus Tocilizumab Canakinumab Vinflunine Trabectedin Ofatumumab Certolizumab pegol Pazopanib Bendamustine Golimumab Fingolimod Eribulin Fluorouracil + Salicylic acid Ipilimumab Belatacept Belimumab Aminolevulinic acid hydrochloride Vemurafenib Cabazitaxel Paclitaxel albumin Catumaxomab Vandetanib Doxorubicin liposomal pegylated Crizotinib Ruxolitinib Axitinib Pixantrone Brentuximab vedotin Decitabine Tegafur + Gimeracil + Oteracil Pertuzumab Pirfenidone Bosutinib Vismodegib Dabrafenib Pomalidomide Regorafenib Afatinib Ponatinib Trastuzumab emtansine Teriflunomide Vedolizumab Siltuximab Obinutuzumab Trametinib Idelalisib Cabozantinib Ibrutinib Ramucirumab Apremilast Nintedanib Secukinumab Olaparib Lenvatinib Nivolumab Pembrolizumab Ceritinib Carfilzomib Blinatumomab Altretamine Irinotecan liposomal pegylated Daunorubicin + Cytarabine The subset excludes VMPs and AMPs that have the following drug forms: Cream Gel Mouthwash Ointment Paste Eye drops Eye ointment Eye gel Ear/eye drops solution Ear/eye/nose drops solution Cutaneous solution

Status

Subset Status :   
Draft for Trial Use
Subset Status Date :   
Jun 12, 2019
Owner (Organisation name) :   
NHS Digital

Purpose and Scope

Usage 1 :

   
Usage Type :    
Intended
Usage Description :    
Intended for secondary uses purposes. Management information to support counts for establishing Enhanced Services activity used to determine Practice payments. Information on the specific business rules can be found here: https://digital.nhs.uk/data-and-information/data-collections-and-data-sets/data-collections/quality-and-outcomes-framework-qof These subsets are created using the XML format dm+d data and so within these subsets a small number of concepts are inactive (status 2 or 10) in the International Release. The origin of these inactive concepts is the native XML dm+d and they are now inactive in the new International Release due to natural movement and updating of the International Release content. Work is underway to update the dm+d concepts to the new International release identifiers; at this point this mismatch will be resolved. If using the dm+d in SNOMED CT format the International Release relationships will enable migration to the replacement concept. This subset identifies the immunosuppressant drug codes that to be used to identify patients are eligible under the Enhanced Services Pneumococcal vaccination and immunisation programme and Seasonal Flu vaccination and immunisation programme 2016-2017
Geographic Usage :    
England
Usage Categories:    
 Administrative; General practice


Scope :

   
Inclusion Criteria :   
Gender - not specified; Sex - not specified
Subject Category :   
Prescribing; Health Care.Primary care; Chemicals and Drugs

Publication

Subset Release Category :   
UK Drug Extension
Language :   
en
Folder Name :   
EnhancedServices
File Name :   
Enhanced Services Immunosuppressant drugs

Subset Licence Type :   
IHTSDO SNOMED CT® Licence; UKTC SNOMED CT® Licence; Open Government Licence

Metadata Version :   
5.0
Last Updated :   
Jun 11, 2019

Related Links

Subset download with descriptions :

UK Drug Extension releases